QAV-680
QAV-680 is a novel pharmaceutical compound currently under investigation for its potential therapeutic applications in the treatment of asthma and other allergic diseases. It is classified as a selective antagonist of the Cysteinyl leukotriene receptor 1 (CysLT1), which plays a significant role in the pathophysiology of these conditions.
Mechanism of Action[edit | edit source]
QAV-680 functions by inhibiting the action of cysteinyl leukotrienes, which are inflammatory mediators derived from arachidonic acid through the lipoxygenase pathway. These leukotrienes bind to CysLT1 receptors, leading to bronchoconstriction, increased vascular permeability, and mucus secretion, all of which contribute to the symptoms of asthma and allergic rhinitis. By blocking these receptors, QAV-680 reduces these inflammatory responses, thereby alleviating symptoms.
Pharmacokinetics[edit | edit source]
The pharmacokinetic profile of QAV-680 is characterized by its oral bioavailability, metabolic stability, and half-life, which are critical for its efficacy as a therapeutic agent. Studies have shown that QAV-680 is well-absorbed in the gastrointestinal tract and undergoes hepatic metabolism. The primary route of excretion is renal.
Clinical Trials[edit | edit source]
QAV-680 is currently in Phase II clinical trials, where its safety and efficacy are being evaluated in patients with moderate to severe asthma. Preliminary results have shown a significant reduction in asthma exacerbations and improvement in lung function tests compared to placebo.
Potential Side Effects[edit | edit source]
As with any pharmacological agent, QAV-680 may have side effects. Commonly reported adverse effects include headache, nausea, and dizziness. Long-term safety data are still being collected.
Research and Development[edit | edit source]
The development of QAV-680 is part of a broader effort to create more effective treatments for asthma and allergic diseases, which affect millions of people worldwide. The compound was discovered through a targeted drug discovery program aimed at identifying potent and selective CysLT1 antagonists.
Also see[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
